

# Nesrina Imami

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2237943/publications.pdf>

Version: 2024-02-01

75  
papers

1,852  
citations

279798

23  
h-index

276875

41  
g-index

77  
all docs

77  
docs citations

77  
times ranked

2378  
citing authors

#	ARTICLE	IF	CITATIONS
1	Progesterone-Related Immune Modulation of Pregnancy and Labor. <i>Frontiers in Endocrinology</i> , 2019, 10, 198.	3.5	133
2	Loss of CD4+T Cell Proliferative Ability but Not Loss of Human Immunodeficiency Virus Type 1 Specificity Equates with Progression to Disease. <i>Journal of Infectious Diseases</i> , 2000, 182, 792-798.	4.0	126
3	Toll-like Receptor 4 Mediates Innate Immunity to Kaposi Sarcoma Herpesvirus. <i>Cell Host and Microbe</i> , 2008, 4, 470-483.	11.0	98
4	A Balanced Type 1/Type 2 Response Is Associated with Long-Term Nonprogressive Human Immunodeficiency Virus Type 1 Infection. <i>Journal of Virology</i> , 2002, 76, 9011-9023.	3.4	91
5	Identification of Kaposi's Sarcoma-Associated Herpesvirus (KSHV)-Specific Cytotoxic T-Lymphocyte Epitopes and Evaluation of Reconstitution of KSHV-Specific Responses in Human Immunodeficiency Virus Type 1-Infected Patients Receiving Highly Active Antiretroviral Therapy. <i>Journal of Virology</i> , 2002, 76, 2634-2640.	3.4	91
6	Assessment of Type 1 and Type 2 Cytokines in HIV Type 1-Infected Individuals: Impact of Highly Active Antiretroviral Therapy. <i>AIDS Research and Human Retroviruses</i> , 1999, 15, 1499-1508.	1.1	85
7	Switch from inhibitory to activating NKG2 receptor expression in HIV-1 infection: lack of reversion with highly active antiretroviral therapy. <i>Aids</i> , 2005, 19, 1761-1769.	2.2	81
8	Old Rhesus Macaques Treated with Interleukin-7 Show Increased TREC Levels And Respond Well to Influenza Vaccination. <i>Rejuvenation Research</i> , 2007, 10, 5-18.	1.8	78
9	Effects of combination chemotherapy and highly active antiretroviral therapy on immune parameters in HIV-1 associated lymphoma. <i>Aids</i> , 2002, 16, 531-536.	2.2	76
10	Changes in T Cell and Dendritic Cell Phenotype from Mid to Late Pregnancy Are Indicative of a Shift from Immune Tolerance to Immune Activation. <i>Frontiers in Immunology</i> , 2017, 8, 1138.	4.8	64
11	Progesterone Modulation of Pregnancy-Related Immune Responses. <i>Frontiers in Immunology</i> , 2018, 9, 1293.	4.8	60
12	Molecular quantitation of thymic output in mice and the effect of IL-7. <i>European Journal of Immunology</i> , 2002, 32, 2827-2836.	2.9	55
13	Kaposi's Sarcoma-Associated Herpesvirus Cytotoxic T Lymphocytes Recognize and Target Darwinian Positively Selected Autologous K1 Epitopes. <i>Journal of Virology</i> , 2003, 77, 4306-4314.	3.4	45
14	A point mutation in CD45 may be associated with an increased risk of HIV-1 infection. <i>Aids</i> , 2001, 15, 1892-1894.	2.2	44
15	Distinct Patterns of Peripheral HIV-1-Specific Interferon- $\gamma$ Responses in Exposed HIV-1-Seronegative Individuals. <i>Journal of Infectious Diseases</i> , 2004, 189, 1705-1713.	4.0	34
16	Immune responses and reconstitution in HIV-1 infected individuals: impact of anti-retroviral therapy, cytokines and therapeutic vaccination. <i>Immunology Letters</i> , 2001, 79, 63-76.	2.5	32
17	Initiation of Antiretroviral Therapy During Recent HIV-1 Infection Results in Lower Residual Viral Reservoirs. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2004, 36, 783-790.	2.1	32
18	The gp200-MR6 molecule which is functionally associated with the IL-4 receptor modulates B cell phenotype and is a novel member of the human macrophage mannose receptor family. <i>European Journal of Immunology</i> , 1998, 28, 4071-4083.	2.9	31

#	ARTICLE	IF	CITATIONS
19	Thymic Output during Initial Highly Active Antiretroviral Therapy (HAART) and during HAART Supplementation with Interleukin 2 and/or with HIV Type 1 Immunogen (Remune). <i>AIDS Research and Human Retroviruses</i> , 2003, 19, 103-109.	1.1	31
20	Are Long-Term Non-Progressors Very Slow Progressors? Insights from the Chelsea and Westminster HIV Cohort, 1988–2010. <i>PLoS ONE</i> , 2012, 7, e29844.	2.5	30
21	Plasma IL-6 as a marker of mycobacterial immune restoration disease in HIV-1 infection. <i>Aids</i> , 2003, 17, 1411-1413.	2.2	29
22	Expression of PD-L1, a marker of disease status, is not reduced by HAART in aviraemic patients. <i>Aids</i> , 2007, 21, 1379-1381.	2.2	27
23	Enhanced T-Cell Maturation, Differentiation and Function in HIV-1-Infected Individuals after Growth Hormone and Highly Active Antiretroviral Therapy. <i>Antiviral Therapy</i> , 2004, 9, 67-75.	1.0	25
24	ASSOCIATION BETWEEN INTERLEUKIN-4-PRODUCING T LYMPHOCYTE FREQUENCIES AND REDUCED RISK OF GRAFT-VERSUS-HOST DISEASE1. <i>Transplantation</i> , 1998, 65, 979-988.	1.0	24
25	HIV Type 1 Antigen-Responsive CD4+T-Lymphocytes in Exposed Yet HIV Type 1 Seronegative Ugandans. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 67-75.	1.1	23
26	Inhibition of alloreactivity by mAb MR6: differential effects on IL-2- and IL-4-producing human T cells. <i>International Immunology</i> , 1994, 6, 1575-1584.	4.0	22
27	Transient Nature of Long-Term Nonprogression and Broad Virus-Specific Proliferative T-Cell Responses with Sustained Thymic Output in HIV-1 Controllers. <i>PLoS ONE</i> , 2009, 4, e5474.	2.5	22
28	The Exon A (C77G) Mutation Is a Common Cause of Abnormal CD45 Splicing in Humans. <i>Journal of Immunology</i> , 2001, 166, 6144-6148.	0.8	21
29	Expression of the common heat-shock protein receptor CD91 is increased on monocytes of exposed yet HIV-1-seronegative subjects. <i>Journal of Leukocyte Biology</i> , 2005, 78, 37-42.	3.3	21
30	A phase I, randomized study of combined IL-2 and therapeutic immunisation with antiretroviral therapy. <i>Journal of Immune Based Therapies and Vaccines</i> , 2007, 5, 6.	2.4	21
31	CCR5 Antagonism Impacts Vaccination Response and Immune Profile in HIV-1 Infection. <i>Molecular Medicine</i> , 2012, 18, 1240-1248.	4.4	21
32	Therapeutic vaccines in HIV. 1 infection. <i>Immunological Reviews</i> , 1999, 170, 173-182.	6.0	19
33	Effects of recombinant human growth hormone on HIV-1-specific T-cell responses, thymic output and proviral DNA in patients on HAART: 48-week follow-up. <i>Journal of Immune Based Therapies and Vaccines</i> , 2008, 6, 7.	2.4	19
34	Long-Term Non-Progression and Broad HIV-1-Specific Proliferative T-Cell Responses. <i>Frontiers in Immunology</i> , 2013, 4, 58.	4.8	19
35	Programmed death ligand 1 (PD-L1) expression influences the immune-tolerogenic microenvironment in antiretroviral therapy-refractory Kaposi's sarcoma: A pilot study. <i>Oncolmmunology</i> , 2017, 6, e1304337.	4.6	15
36	Therapeutic immunisation plus cytokine and hormone therapy improves CD4 T-cell counts, restores anti-HIV-1 responses and reduces immune activation in treated chronic HIV-1 infection. <i>Vaccine</i> , 2014, 32, 7005-7013.	3.8	14

#	ARTICLE	IF	CITATIONS
37	Development of immunotherapeutic strategies for HIV-1. <i>Expert Opinion on Biological Therapy</i> , 2001, 1, 803-816.	3.1	13
38	Interleukin-2-associated viral breakthroughs induce HIV-1-specific CD4 T cell responses in patients on fully suppressive highly active antiretroviral therapy. <i>Aids</i> , 2003, 17, 628-629.	2.2	13
39	Rapid qualitative and quantitative analysis of T-cell responses in HIV-1-infected individuals receiving successful HAART and HIV-1 sero-negative controls: Concomitant assessment of perforin, IFN- $\gamma$ and IL-4 secretion. <i>Journal of Immunological Methods</i> , 2006, 308, 216-230.	1.4	12
40	A new antigen scanning strategy for monitoring HIV-1 specific T-cell immune responses. <i>Journal of Immunological Methods</i> , 2012, 375, 46-56.	1.4	11
41	Enhanced T-cell maturation, differentiation and function in HIV-1-infected individuals after growth hormone and highly active antiretroviral therapy. <i>Antiviral Therapy</i> , 2004, 9, 67-75.	1.0	11
42	Novel approach to recognition of predicted HIV-1 Gag B $\alpha$ 3501-restricted CD8 T-cell epitopes by HLA-B $\alpha$ 3501+ patients: Confirmation by quantitative ELISpot analyses and characterisation using multimers. <i>Journal of Immunological Methods</i> , 2009, 341, 76-85.	1.4	10
43	Tetanus vaccination with IL-2 during highly active antiretroviral therapy induces sustained and pronounced specific CD4 T-cell responses. <i>Aids</i> , 2004, 18, 2199-2202.	2.2	9
44	The importance of standardisation of laboratory evaluations in HIV vaccine trials. <i>Microbes and Infection</i> , 2005, 7, 1424-32.	1.9	9
45	Specificity of anti-human leukocyte antigen antibody responses after immunization with Remune, an inactivated HIV-1 vaccine. <i>Aids</i> , 2007, 21, 375-377.	2.2	9
46	HIV Type 1-Specific Inter- and Intrasubtype Cellular Immune Responses in HIV Type 1-Infected Ugandans. <i>AIDS Research and Human Retroviruses</i> , 2004, 20, 763-771.	1.1	8
47	Pregnancy-related immune suppression leads to altered influenza vaccine recall responses. <i>Clinical Immunology</i> , 2019, 208, 108254.	3.2	8
48	Infection with multiple HIV-1 founder variants is associated with lower viral replicative capacity, faster CD4+ T cell decline and increased immune activation during acute infection. <i>PLoS Pathogens</i> , 2020, 16, e1008853.	4.7	8
49	Combined use of cytokines, hormones and therapeutic vaccines during effective antiretroviral therapy. <i>Future HIV Therapy</i> , 2007, 1, 171-179.	0.4	7
50	CCR2/64I mutation detection in a HIV-1-positive patient with slow CD4 T-cell decline and delay in disease progression. <i>International Journal of STD and AIDS</i> , 2005, 16, 392-395.	1.1	6
51	Short Communication: Therapeutic Immunization Benefits Mucosal-Associated Invariant T Cell Recovery in Contrast to Interleukin-2, Granulocyte-Macrophage Colony-Stimulating Factor, and Recombinant Human Growth Hormone Addition in HIV-1+ Treated Patients: Individual Case Reports from Phase I Trial. <i>AIDS Research and Human Retroviruses</i> , 2019, 35, 306-309.	1.1	6
52	Three-Year Immune Reconstitution in PI-Sparing and PI-Containing Antiretroviral Regimens in Advanced HIV-1 Disease. <i>Antiviral Therapy</i> , 2007, 12, 553-558.	1.0	6
53	Long-term increase of CD4+ central memory cells in HIV-1-infected individuals by therapeutic HIV-1 rgp160 immunization. <i>Vaccine</i> , 2008, 26, 5107-5110.	3.8	5
54	Multifarious immunotherapeutic approaches to cure HIV-1 infection. <i>Human Vaccines and Immunotherapeutics</i> , 2015, 11, 2287-2293.	3.3	5

#	ARTICLE	IF	CITATIONS
55	Immune reconstitution in HIV-1-infected patients. <i>Current Opinion in Investigational Drugs</i> , 2002, 3, 1138-45.	2.3	5
56	Recent HIV-1 infection in a high-risk Ugandan cohort: implications for Phase IIB test-of-concept HIV vaccine trials. <i>Pharmacogenomics</i> , 2007, 8, 409-414.	1.3	4
57	T-cell dysfunction in HIV-1 infection: targeting the inhibitors. <i>HIV Therapy</i> , 2010, 4, 83-99.	0.6	4
58	African ancestry and innate immunity contribute to the incidence of multicentric Castleman's disease in HIV-1/Kaposi's sarcoma herpesvirus-coinfected individuals. <i>Future Virology</i> , 2012, 7, 729-734.	1.8	4
59	Enrichment of HLA Types and Single-Nucleotide Polymorphism Associated With Non-progression in a Strictly Defined Cohort of HIV-1 Controllers. <i>Frontiers in Immunology</i> , 2017, 8, 746.	4.8	4
60	T-cell signalling in antiretroviral-treated, aviraemic HIV-1-positive individuals is present in a raised state of basal activation that contributes to T-cell hyporesponsiveness. <i>Aids</i> , 2011, 25, 1981-1986.	2.2	3
61	Pregnancy Gestation Impacts on HIV-1-Specific Granzyme B Response and Central Memory CD4 T Cells. <i>Frontiers in Immunology</i> , 2020, 11, 153.	4.8	3
62	Mechanisms of loss of HIV-1-specific T-cell responses. <i>Journal of HIV Therapy</i> , 2002, 7, 30-4.	0.6	3
63	K21-Antigen: A Molecule Shared by the Microenvironments of the Human Thymus and Germinal Centers. <i>Autoimmunity</i> , 1998, 6, 41-52.	0.6	2
64	Twenty years of HIV-1 research: what the future holds. <i>Nature Immunology</i> , 2003, 4, 501-501.	14.5	1
65	The challenge of developing an effective HIV-1 vaccine. <i>Drug Discovery Today: Therapeutic Strategies</i> , 2004, 1, 461-467.	0.5	1
66	A case of multidrug resistant primary HIV infection with delayed CD4 T-cell count decline despite low viral load, treated with interleukin-2. <i>Aids</i> , 2006, 20, 1564-1565.	2.2	1
67	Eltrombopag: More Than Just a Thrombopoietin Receptor Agonist (TPO-RA) in Immune Thrombocytopenia (ITP). <i>Blood</i> , 2019, 134, 2364-2364.	1.4	1
68	Timing of antiretroviral therapy: an immunological perspective. <i>Journal of HIV Therapy</i> , 2003, 8, 15-8.	0.6	1
69	An anniversary without celebration?. <i>Nature Immunology</i> , 2006, 7, 893-893.	14.5	0
70	A stepwise advance out of the shadows: leading HIV to its clearance. <i>Future Virology</i> , 2015, 10, 1263-1266.	1.8	0
71	Interleukin-21 Receptor Expression on CD8 T Cells: A Potential Biomarker of HIV-1 Disease State and Trajectory. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
72	Title is missing!. , 2020, 16, e1008853.		0

#	ARTICLE	IF	CITATIONS
73	Title is missing!. , 2020, 16, e1008853.		0
74	Title is missing!. , 2020, 16, e1008853.		0
75	Title is missing!.. , 2020, 16, e1008853.		0